Occult axillary node metastases in breast cancer are prognostically significant: Results in 368 node-negative patients with 20-year follow-up

被引:116
|
作者
Tan, Lee K.
Giri, Dilip
Hummer, Amanda J.
Panageas, Katherine S.
Brogi, Edi
Norton, Larry
Hudis, Clifford
Borgen, Patrick I.
Cody, Hiram S., III [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
关键词
D O I
10.1200/JCO.2007.12.6425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose In breast cancer, sentinel lymph node (SLN) biopsy allows the routine performance of serial sections and/or immunohistochemical (IHC) staining to detect occult metastases missed by conventional techniques. However, there is no consensus regarding the optimal method for pathologic examination of SLN, or the prognostic significance of SLN micrometastases. Patients and Methods In 368 patients with axillary node-negative invasive breast cancer, treated between 1976 and 1978 by mastectomy, axillary dissection, and no systemic therapy, we reexamined the axillary tissue blocks following our current pathologic protocol for SLN. Occult lymph node metastases were categorized by pattern of staining (immunohistochemically positive or negative [IHC +/-], hematoxylin-eosin staining positive or negative [H&E±]), number of positive nodes (0, 1, > 1), number of metastatic cells (0, 1 to 20, 21 to 100, > 100), and largest cluster size (<= 0.2 mm [pN0(i+)], 0.3 to 2.0 mm [pN1(mi)], > 2.0 mm [pN1a]). We report 20-year results as overall survival (OS), disease-free survival (DFS), and disease-specific death (DSD). Results A total of 23% of patients (83 of 368) were converted to node-positive. Of these, 73% were <= 0.2 mm in size (pN0(i+)), 20% were 0.3 to 2.0 mm (pN1(mi)), and 6% were more than 2 mm (pN1a). On univariate and multivariate analysis, pattern of staining, number of positive nodes, number of metastatic cells, and cluster size were all significantly related to both DFS and DSD. On multivariate analysis, each of these measures had significance comparable to, or greater than, tumor size, grade or lymphovascular invasion. Conclusion In breast cancer patients staged node-negative by conventional single-section pathology, occult axillary node metastases detected by our current pathologic protocol for SLN are prognostically significant.
引用
收藏
页码:1803 / 1809
页数:7
相关论文
共 50 条
  • [31] Survival Impact of Occult Metastases in NSABP B-32: Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Breast Cancer
    Weaver, D. L.
    Ashikaga, T.
    Krag, D. N.
    Skelly, J. M.
    Anderson, S. J.
    Harlow, S. P.
    Julian, T. B.
    Mamounas, E. P.
    Wolmark, N.
    LABORATORY INVESTIGATION, 2011, 91 : 69A - 69A
  • [32] Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: A long term follow-up analysis
    Torrenga, H
    Fabry, H
    Van der Sijp, JRM
    Van Diest, PJ
    Pijpers, R
    Meijer, S
    JOURNAL OF SURGICAL ONCOLOGY, 2004, 88 (01) : 4 - 7
  • [33] Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial
    Canavese, Giuseppe
    Bruzzi, Paolo
    Catturich, Alessandra
    Tomei, Daniela
    Carli, Franca
    Garrone, Elsa
    Spinaci, Stefano
    Lacopo, Federico
    Tinterri, Corrado
    Dozin, Beatrice
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (08) : 2494 - 2500
  • [34] Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial
    Giuseppe Canavese
    Paolo Bruzzi
    Alessandra Catturich
    Daniela Tomei
    Franca Carli
    Elsa Garrone
    Stefano Spinaci
    Federico Lacopo
    Corrado Tinterri
    Beatrice Dozin
    Annals of Surgical Oncology, 2016, 23 : 2494 - 2500
  • [35] Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment
    Galimberti, V.
    Fontana, S. K. Ribeiro
    Maisonneuve, P.
    Steccanella, F.
    Vento, A. R.
    Intra, M.
    Naninato, P.
    Caldarella, P.
    Iorfida, M.
    Colleoni, M.
    Viale, G.
    Grana, C. M.
    Rotmensz, N.
    Luini, A.
    EJSO, 2016, 42 (03): : 361 - 368
  • [36] Partial Lower Axillary Dissection for Patients with Clinically Node-negative Breast Cancer
    Kodama, H.
    Mise, K.
    Kan, N.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (06) : 2336 - 2345
  • [37] Can sentinel node biopsy avoid axillary dissection in clinically node-negative breast cancer patients?
    Galimberti, V
    Zurrida, S
    Zucali, P
    Luini, A
    BREAST, 1998, 7 (01): : 8 - 10
  • [38] Sentinel node biopsy versus conventional axillary dissection in clinically node-negative breast cancer patients
    Bear, HD
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 1) : S7 - S7
  • [39] Sentinel node biopsy versus conventional axillary dissection in clinically node-negative breast cancer patients
    HD Bear
    Breast Cancer Research, 7
  • [40] The prognostic significance of total lymph node number in patients with axillary lymph node-negative breast cancer
    Mersin, H
    Yildirim, E
    Bulut, H
    Berberoglu, U
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (02): : 132 - 138